Podcast appearances and mentions of Jay B Wish

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

Go online to PeerView.com/MVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of experts offers insight into best practices regarding the treatment of anemia associated with chronic kidney disease (CKD) and emphasizes that the success of employing current (and future) treatments falls on the members of the interdisciplinary nephrology care team. Foundational guidance is combined with a discussion of real cases to further highlight new developments in the management of anemia associated with CKD and provide practical guidance on the integration of such advances. Upon completion of this activity, participants will be able to: Describe the prevalence, clinical impact, and pathogenesis of anemia in CKD, Identify benefits and limitations associated with current management approaches to anemia in CKD, Recognize the mechanism of action of emerging hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in the management of anemia in CKD, Assess safety and efficacy data supporting HIF-PH inhibitor use in patients with anemia in CKD, Employ strategies to treat anemia in CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/MVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of experts offers insight into best practices regarding the treatment of anemia associated with chronic kidney disease (CKD) and emphasizes that the success of employing current (and future) treatments falls on the members of the interdisciplinary nephrology care team. Foundational guidance is combined with a discussion of real cases to further highlight new developments in the management of anemia associated with CKD and provide practical guidance on the integration of such advances. Upon completion of this activity, participants will be able to: Describe the prevalence, clinical impact, and pathogenesis of anemia in CKD, Identify benefits and limitations associated with current management approaches to anemia in CKD, Recognize the mechanism of action of emerging hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in the management of anemia in CKD, Assess safety and efficacy data supporting HIF-PH inhibitor use in patients with anemia in CKD, Employ strategies to treat anemia in CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/MVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of experts offers insight into best practices regarding the treatment of anemia associated with chronic kidney disease (CKD) and emphasizes that the success of employing current (and future) treatments falls on the members of the interdisciplinary nephrology care team. Foundational guidance is combined with a discussion of real cases to further highlight new developments in the management of anemia associated with CKD and provide practical guidance on the integration of such advances. Upon completion of this activity, participants will be able to: Describe the prevalence, clinical impact, and pathogenesis of anemia in CKD, Identify benefits and limitations associated with current management approaches to anemia in CKD, Recognize the mechanism of action of emerging hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in the management of anemia in CKD, Assess safety and efficacy data supporting HIF-PH inhibitor use in patients with anemia in CKD, Employ strategies to treat anemia in CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/MVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of experts offers insight into best practices regarding the treatment of anemia associated with chronic kidney disease (CKD) and emphasizes that the success of employing current (and future) treatments falls on the members of the interdisciplinary nephrology care team. Foundational guidance is combined with a discussion of real cases to further highlight new developments in the management of anemia associated with CKD and provide practical guidance on the integration of such advances. Upon completion of this activity, participants will be able to: Describe the prevalence, clinical impact, and pathogenesis of anemia in CKD, Identify benefits and limitations associated with current management approaches to anemia in CKD, Recognize the mechanism of action of emerging hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in the management of anemia in CKD, Assess safety and efficacy data supporting HIF-PH inhibitor use in patients with anemia in CKD, Employ strategies to treat anemia in CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/MVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of experts offers insight into best practices regarding the treatment of anemia associated with chronic kidney disease (CKD) and emphasizes that the success of employing current (and future) treatments falls on the members of the interdisciplinary nephrology care team. Foundational guidance is combined with a discussion of real cases to further highlight new developments in the management of anemia associated with CKD and provide practical guidance on the integration of such advances. Upon completion of this activity, participants will be able to: Describe the prevalence, clinical impact, and pathogenesis of anemia in CKD, Identify benefits and limitations associated with current management approaches to anemia in CKD, Recognize the mechanism of action of emerging hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in the management of anemia in CKD, Assess safety and efficacy data supporting HIF-PH inhibitor use in patients with anemia in CKD, Employ strategies to treat anemia in CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/MVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of experts offers insight into best practices regarding the treatment of anemia associated with chronic kidney disease (CKD) and emphasizes that the success of employing current (and future) treatments falls on the members of the interdisciplinary nephrology care team. Foundational guidance is combined with a discussion of real cases to further highlight new developments in the management of anemia associated with CKD and provide practical guidance on the integration of such advances. Upon completion of this activity, participants will be able to: Describe the prevalence, clinical impact, and pathogenesis of anemia in CKD, Identify benefits and limitations associated with current management approaches to anemia in CKD, Recognize the mechanism of action of emerging hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in the management of anemia in CKD, Assess safety and efficacy data supporting HIF-PH inhibitor use in patients with anemia in CKD, Employ strategies to treat anemia in CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/MVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of experts offers insight into best practices regarding the treatment of anemia associated with chronic kidney disease (CKD) and emphasizes that the success of employing current (and future) treatments falls on the members of the interdisciplinary nephrology care team. Foundational guidance is combined with a discussion of real cases to further highlight new developments in the management of anemia associated with CKD and provide practical guidance on the integration of such advances. Upon completion of this activity, participants will be able to: Describe the prevalence, clinical impact, and pathogenesis of anemia in CKD, Identify benefits and limitations associated with current management approaches to anemia in CKD, Recognize the mechanism of action of emerging hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in the management of anemia in CKD, Assess safety and efficacy data supporting HIF-PH inhibitor use in patients with anemia in CKD, Employ strategies to treat anemia in CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/MVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of experts offers insight into best practices regarding the treatment of anemia associated with chronic kidney disease (CKD) and emphasizes that the success of employing current (and future) treatments falls on the members of the interdisciplinary nephrology care team. Foundational guidance is combined with a discussion of real cases to further highlight new developments in the management of anemia associated with CKD and provide practical guidance on the integration of such advances. Upon completion of this activity, participants will be able to: Describe the prevalence, clinical impact, and pathogenesis of anemia in CKD, Identify benefits and limitations associated with current management approaches to anemia in CKD, Recognize the mechanism of action of emerging hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in the management of anemia in CKD, Assess safety and efficacy data supporting HIF-PH inhibitor use in patients with anemia in CKD, Employ strategies to treat anemia in CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/MVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of experts offers insight into best practices regarding the treatment of anemia associated with chronic kidney disease (CKD) and emphasizes that the success of employing current (and future) treatments falls on the members of the interdisciplinary nephrology care team. Foundational guidance is combined with a discussion of real cases to further highlight new developments in the management of anemia associated with CKD and provide practical guidance on the integration of such advances. Upon completion of this activity, participants will be able to: Describe the prevalence, clinical impact, and pathogenesis of anemia in CKD, Identify benefits and limitations associated with current management approaches to anemia in CKD, Recognize the mechanism of action of emerging hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in the management of anemia in CKD, Assess safety and efficacy data supporting HIF-PH inhibitor use in patients with anemia in CKD, Employ strategies to treat anemia in CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/MVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of experts offers insight into best practices regarding the treatment of anemia associated with chronic kidney disease (CKD) and emphasizes that the success of employing current (and future) treatments falls on the members of the interdisciplinary nephrology care team. Foundational guidance is combined with a discussion of real cases to further highlight new developments in the management of anemia associated with CKD and provide practical guidance on the integration of such advances. Upon completion of this activity, participants will be able to: Describe the prevalence, clinical impact, and pathogenesis of anemia in CKD, Identify benefits and limitations associated with current management approaches to anemia in CKD, Recognize the mechanism of action of emerging hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in the management of anemia in CKD, Assess safety and efficacy data supporting HIF-PH inhibitor use in patients with anemia in CKD, Employ strategies to treat anemia in CKD in accordance with current evidence, expert recommendations, and individual patient needs.

Go online to PeerView.com/ETT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Anemia is a common complication of chronic kidney disease (CKD), which represents a major worldwide burden on public health, particularly in aging populations. Anemia affects the majority of patients with advanced CKD and is associated with increased cardiovascular risk, hospitalization, and mortality. Anemia in CKD is predominantly because of a relative deficiency in erythropoietin (EPO) production by the kidney, although concomitant functional and/or absolute iron deficiency and systemic and local inflammation also frequently contribute to its induction and maintenance. The current standard of care for anemia secondary to CKD is the use of injectable erythropoiesis-stimulating agents (ESAs), alone or in combination with intravenous or oral iron supplementation. While ESAs have been shown to be effective in treating anemia for many patients with CKD, they have some well-recognized limitations. Thus, alternative treatments that limit EPO exposure would be useful additions to the therapeutic armamentarium for anemia in CKD. Stabilization of hypoxia-inducible factor (HIF) via prolyl-hydroxylase (PH) domain inhibition represents a potentially promising new therapeutic approach to treat anemia secondary to CKD. Activation of HIF orchestrates a coordinated response to promote erythropoiesis through the stimulation of endogenous EPO production, increased uptake of iron, and mobilization of iron stores. Indeed, several HIF-PH inhibitors are currently in development for the treatment of anemia in CKD, and available clinical trial data suggest that HIF-PH inhibitors offer a number of advantages over ESAs. In this activity, based on a live symposium, experts offer insight into best practices regarding the treatment of CKD-associated anemia and the important emerging evidence for HIF-PH inhibitors in settings where conventional ESA therapy is often of limited efficacy. Foundational guidance is combined with a discussion of real cases. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia as a result of CKD, Summarize current clinical trial data regarding the efficacy and safety of HIF-PH inhibitors for the treatment of anemia because of CKD in both nondialysis-dependent and dialysis-dependent patients, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/ETT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Anemia is a common complication of chronic kidney disease (CKD), which represents a major worldwide burden on public health, particularly in aging populations. Anemia affects the majority of patients with advanced CKD and is associated with increased cardiovascular risk, hospitalization, and mortality. Anemia in CKD is predominantly because of a relative deficiency in erythropoietin (EPO) production by the kidney, although concomitant functional and/or absolute iron deficiency and systemic and local inflammation also frequently contribute to its induction and maintenance. The current standard of care for anemia secondary to CKD is the use of injectable erythropoiesis-stimulating agents (ESAs), alone or in combination with intravenous or oral iron supplementation. While ESAs have been shown to be effective in treating anemia for many patients with CKD, they have some well-recognized limitations. Thus, alternative treatments that limit EPO exposure would be useful additions to the therapeutic armamentarium for anemia in CKD. Stabilization of hypoxia-inducible factor (HIF) via prolyl-hydroxylase (PH) domain inhibition represents a potentially promising new therapeutic approach to treat anemia secondary to CKD. Activation of HIF orchestrates a coordinated response to promote erythropoiesis through the stimulation of endogenous EPO production, increased uptake of iron, and mobilization of iron stores. Indeed, several HIF-PH inhibitors are currently in development for the treatment of anemia in CKD, and available clinical trial data suggest that HIF-PH inhibitors offer a number of advantages over ESAs. In this activity, based on a live symposium, experts offer insight into best practices regarding the treatment of CKD-associated anemia and the important emerging evidence for HIF-PH inhibitors in settings where conventional ESA therapy is often of limited efficacy. Foundational guidance is combined with a discussion of real cases. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia as a result of CKD, Summarize current clinical trial data regarding the efficacy and safety of HIF-PH inhibitors for the treatment of anemia because of CKD in both nondialysis-dependent and dialysis-dependent patients, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/ETT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Anemia is a common complication of chronic kidney disease (CKD), which represents a major worldwide burden on public health, particularly in aging populations. Anemia affects the majority of patients with advanced CKD and is associated with increased cardiovascular risk, hospitalization, and mortality. Anemia in CKD is predominantly because of a relative deficiency in erythropoietin (EPO) production by the kidney, although concomitant functional and/or absolute iron deficiency and systemic and local inflammation also frequently contribute to its induction and maintenance. The current standard of care for anemia secondary to CKD is the use of injectable erythropoiesis-stimulating agents (ESAs), alone or in combination with intravenous or oral iron supplementation. While ESAs have been shown to be effective in treating anemia for many patients with CKD, they have some well-recognized limitations. Thus, alternative treatments that limit EPO exposure would be useful additions to the therapeutic armamentarium for anemia in CKD. Stabilization of hypoxia-inducible factor (HIF) via prolyl-hydroxylase (PH) domain inhibition represents a potentially promising new therapeutic approach to treat anemia secondary to CKD. Activation of HIF orchestrates a coordinated response to promote erythropoiesis through the stimulation of endogenous EPO production, increased uptake of iron, and mobilization of iron stores. Indeed, several HIF-PH inhibitors are currently in development for the treatment of anemia in CKD, and available clinical trial data suggest that HIF-PH inhibitors offer a number of advantages over ESAs. In this activity, based on a live symposium, experts offer insight into best practices regarding the treatment of CKD-associated anemia and the important emerging evidence for HIF-PH inhibitors in settings where conventional ESA therapy is often of limited efficacy. Foundational guidance is combined with a discussion of real cases. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia as a result of CKD, Summarize current clinical trial data regarding the efficacy and safety of HIF-PH inhibitors for the treatment of anemia because of CKD in both nondialysis-dependent and dialysis-dependent patients, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/ETT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Anemia is a common complication of chronic kidney disease (CKD), which represents a major worldwide burden on public health, particularly in aging populations. Anemia affects the majority of patients with advanced CKD and is associated with increased cardiovascular risk, hospitalization, and mortality. Anemia in CKD is predominantly because of a relative deficiency in erythropoietin (EPO) production by the kidney, although concomitant functional and/or absolute iron deficiency and systemic and local inflammation also frequently contribute to its induction and maintenance. The current standard of care for anemia secondary to CKD is the use of injectable erythropoiesis-stimulating agents (ESAs), alone or in combination with intravenous or oral iron supplementation. While ESAs have been shown to be effective in treating anemia for many patients with CKD, they have some well-recognized limitations. Thus, alternative treatments that limit EPO exposure would be useful additions to the therapeutic armamentarium for anemia in CKD. Stabilization of hypoxia-inducible factor (HIF) via prolyl-hydroxylase (PH) domain inhibition represents a potentially promising new therapeutic approach to treat anemia secondary to CKD. Activation of HIF orchestrates a coordinated response to promote erythropoiesis through the stimulation of endogenous EPO production, increased uptake of iron, and mobilization of iron stores. Indeed, several HIF-PH inhibitors are currently in development for the treatment of anemia in CKD, and available clinical trial data suggest that HIF-PH inhibitors offer a number of advantages over ESAs. In this activity, based on a live symposium, experts offer insight into best practices regarding the treatment of CKD-associated anemia and the important emerging evidence for HIF-PH inhibitors in settings where conventional ESA therapy is often of limited efficacy. Foundational guidance is combined with a discussion of real cases. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia as a result of CKD, Summarize current clinical trial data regarding the efficacy and safety of HIF-PH inhibitors for the treatment of anemia because of CKD in both nondialysis-dependent and dialysis-dependent patients, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/ETT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Anemia is a common complication of chronic kidney disease (CKD), which represents a major worldwide burden on public health, particularly in aging populations. Anemia affects the majority of patients with advanced CKD and is associated with increased cardiovascular risk, hospitalization, and mortality. Anemia in CKD is predominantly because of a relative deficiency in erythropoietin (EPO) production by the kidney, although concomitant functional and/or absolute iron deficiency and systemic and local inflammation also frequently contribute to its induction and maintenance. The current standard of care for anemia secondary to CKD is the use of injectable erythropoiesis-stimulating agents (ESAs), alone or in combination with intravenous or oral iron supplementation. While ESAs have been shown to be effective in treating anemia for many patients with CKD, they have some well-recognized limitations. Thus, alternative treatments that limit EPO exposure would be useful additions to the therapeutic armamentarium for anemia in CKD. Stabilization of hypoxia-inducible factor (HIF) via prolyl-hydroxylase (PH) domain inhibition represents a potentially promising new therapeutic approach to treat anemia secondary to CKD. Activation of HIF orchestrates a coordinated response to promote erythropoiesis through the stimulation of endogenous EPO production, increased uptake of iron, and mobilization of iron stores. Indeed, several HIF-PH inhibitors are currently in development for the treatment of anemia in CKD, and available clinical trial data suggest that HIF-PH inhibitors offer a number of advantages over ESAs. In this activity, based on a live symposium, experts offer insight into best practices regarding the treatment of CKD-associated anemia and the important emerging evidence for HIF-PH inhibitors in settings where conventional ESA therapy is often of limited efficacy. Foundational guidance is combined with a discussion of real cases. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia as a result of CKD, Summarize current clinical trial data regarding the efficacy and safety of HIF-PH inhibitors for the treatment of anemia because of CKD in both nondialysis-dependent and dialysis-dependent patients, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/ETT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Anemia is a common complication of chronic kidney disease (CKD), which represents a major worldwide burden on public health, particularly in aging populations. Anemia affects the majority of patients with advanced CKD and is associated with increased cardiovascular risk, hospitalization, and mortality. Anemia in CKD is predominantly because of a relative deficiency in erythropoietin (EPO) production by the kidney, although concomitant functional and/or absolute iron deficiency and systemic and local inflammation also frequently contribute to its induction and maintenance. The current standard of care for anemia secondary to CKD is the use of injectable erythropoiesis-stimulating agents (ESAs), alone or in combination with intravenous or oral iron supplementation. While ESAs have been shown to be effective in treating anemia for many patients with CKD, they have some well-recognized limitations. Thus, alternative treatments that limit EPO exposure would be useful additions to the therapeutic armamentarium for anemia in CKD. Stabilization of hypoxia-inducible factor (HIF) via prolyl-hydroxylase (PH) domain inhibition represents a potentially promising new therapeutic approach to treat anemia secondary to CKD. Activation of HIF orchestrates a coordinated response to promote erythropoiesis through the stimulation of endogenous EPO production, increased uptake of iron, and mobilization of iron stores. Indeed, several HIF-PH inhibitors are currently in development for the treatment of anemia in CKD, and available clinical trial data suggest that HIF-PH inhibitors offer a number of advantages over ESAs. In this activity, based on a live symposium, experts offer insight into best practices regarding the treatment of CKD-associated anemia and the important emerging evidence for HIF-PH inhibitors in settings where conventional ESA therapy is often of limited efficacy. Foundational guidance is combined with a discussion of real cases. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia as a result of CKD, Summarize current clinical trial data regarding the efficacy and safety of HIF-PH inhibitors for the treatment of anemia because of CKD in both nondialysis-dependent and dialysis-dependent patients, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/ETT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Anemia is a common complication of chronic kidney disease (CKD), which represents a major worldwide burden on public health, particularly in aging populations. Anemia affects the majority of patients with advanced CKD and is associated with increased cardiovascular risk, hospitalization, and mortality. Anemia in CKD is predominantly because of a relative deficiency in erythropoietin (EPO) production by the kidney, although concomitant functional and/or absolute iron deficiency and systemic and local inflammation also frequently contribute to its induction and maintenance. The current standard of care for anemia secondary to CKD is the use of injectable erythropoiesis-stimulating agents (ESAs), alone or in combination with intravenous or oral iron supplementation. While ESAs have been shown to be effective in treating anemia for many patients with CKD, they have some well-recognized limitations. Thus, alternative treatments that limit EPO exposure would be useful additions to the therapeutic armamentarium for anemia in CKD. Stabilization of hypoxia-inducible factor (HIF) via prolyl-hydroxylase (PH) domain inhibition represents a potentially promising new therapeutic approach to treat anemia secondary to CKD. Activation of HIF orchestrates a coordinated response to promote erythropoiesis through the stimulation of endogenous EPO production, increased uptake of iron, and mobilization of iron stores. Indeed, several HIF-PH inhibitors are currently in development for the treatment of anemia in CKD, and available clinical trial data suggest that HIF-PH inhibitors offer a number of advantages over ESAs. In this activity, based on a live symposium, experts offer insight into best practices regarding the treatment of CKD-associated anemia and the important emerging evidence for HIF-PH inhibitors in settings where conventional ESA therapy is often of limited efficacy. Foundational guidance is combined with a discussion of real cases. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia as a result of CKD, Summarize current clinical trial data regarding the efficacy and safety of HIF-PH inhibitors for the treatment of anemia because of CKD in both nondialysis-dependent and dialysis-dependent patients, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/ETT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Anemia is a common complication of chronic kidney disease (CKD), which represents a major worldwide burden on public health, particularly in aging populations. Anemia affects the majority of patients with advanced CKD and is associated with increased cardiovascular risk, hospitalization, and mortality. Anemia in CKD is predominantly because of a relative deficiency in erythropoietin (EPO) production by the kidney, although concomitant functional and/or absolute iron deficiency and systemic and local inflammation also frequently contribute to its induction and maintenance. The current standard of care for anemia secondary to CKD is the use of injectable erythropoiesis-stimulating agents (ESAs), alone or in combination with intravenous or oral iron supplementation. While ESAs have been shown to be effective in treating anemia for many patients with CKD, they have some well-recognized limitations. Thus, alternative treatments that limit EPO exposure would be useful additions to the therapeutic armamentarium for anemia in CKD. Stabilization of hypoxia-inducible factor (HIF) via prolyl-hydroxylase (PH) domain inhibition represents a potentially promising new therapeutic approach to treat anemia secondary to CKD. Activation of HIF orchestrates a coordinated response to promote erythropoiesis through the stimulation of endogenous EPO production, increased uptake of iron, and mobilization of iron stores. Indeed, several HIF-PH inhibitors are currently in development for the treatment of anemia in CKD, and available clinical trial data suggest that HIF-PH inhibitors offer a number of advantages over ESAs. In this activity, based on a live symposium, experts offer insight into best practices regarding the treatment of CKD-associated anemia and the important emerging evidence for HIF-PH inhibitors in settings where conventional ESA therapy is often of limited efficacy. Foundational guidance is combined with a discussion of real cases. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia as a result of CKD, Summarize current clinical trial data regarding the efficacy and safety of HIF-PH inhibitors for the treatment of anemia because of CKD in both nondialysis-dependent and dialysis-dependent patients, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/ETT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Anemia is a common complication of chronic kidney disease (CKD), which represents a major worldwide burden on public health, particularly in aging populations. Anemia affects the majority of patients with advanced CKD and is associated with increased cardiovascular risk, hospitalization, and mortality. Anemia in CKD is predominantly because of a relative deficiency in erythropoietin (EPO) production by the kidney, although concomitant functional and/or absolute iron deficiency and systemic and local inflammation also frequently contribute to its induction and maintenance. The current standard of care for anemia secondary to CKD is the use of injectable erythropoiesis-stimulating agents (ESAs), alone or in combination with intravenous or oral iron supplementation. While ESAs have been shown to be effective in treating anemia for many patients with CKD, they have some well-recognized limitations. Thus, alternative treatments that limit EPO exposure would be useful additions to the therapeutic armamentarium for anemia in CKD. Stabilization of hypoxia-inducible factor (HIF) via prolyl-hydroxylase (PH) domain inhibition represents a potentially promising new therapeutic approach to treat anemia secondary to CKD. Activation of HIF orchestrates a coordinated response to promote erythropoiesis through the stimulation of endogenous EPO production, increased uptake of iron, and mobilization of iron stores. Indeed, several HIF-PH inhibitors are currently in development for the treatment of anemia in CKD, and available clinical trial data suggest that HIF-PH inhibitors offer a number of advantages over ESAs. In this activity, based on a live symposium, experts offer insight into best practices regarding the treatment of CKD-associated anemia and the important emerging evidence for HIF-PH inhibitors in settings where conventional ESA therapy is often of limited efficacy. Foundational guidance is combined with a discussion of real cases. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia as a result of CKD, Summarize current clinical trial data regarding the efficacy and safety of HIF-PH inhibitors for the treatment of anemia because of CKD in both nondialysis-dependent and dialysis-dependent patients, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/ETT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Anemia is a common complication of chronic kidney disease (CKD), which represents a major worldwide burden on public health, particularly in aging populations. Anemia affects the majority of patients with advanced CKD and is associated with increased cardiovascular risk, hospitalization, and mortality. Anemia in CKD is predominantly because of a relative deficiency in erythropoietin (EPO) production by the kidney, although concomitant functional and/or absolute iron deficiency and systemic and local inflammation also frequently contribute to its induction and maintenance. The current standard of care for anemia secondary to CKD is the use of injectable erythropoiesis-stimulating agents (ESAs), alone or in combination with intravenous or oral iron supplementation. While ESAs have been shown to be effective in treating anemia for many patients with CKD, they have some well-recognized limitations. Thus, alternative treatments that limit EPO exposure would be useful additions to the therapeutic armamentarium for anemia in CKD. Stabilization of hypoxia-inducible factor (HIF) via prolyl-hydroxylase (PH) domain inhibition represents a potentially promising new therapeutic approach to treat anemia secondary to CKD. Activation of HIF orchestrates a coordinated response to promote erythropoiesis through the stimulation of endogenous EPO production, increased uptake of iron, and mobilization of iron stores. Indeed, several HIF-PH inhibitors are currently in development for the treatment of anemia in CKD, and available clinical trial data suggest that HIF-PH inhibitors offer a number of advantages over ESAs. In this activity, based on a live symposium, experts offer insight into best practices regarding the treatment of CKD-associated anemia and the important emerging evidence for HIF-PH inhibitors in settings where conventional ESA therapy is often of limited efficacy. Foundational guidance is combined with a discussion of real cases. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia as a result of CKD, Summarize current clinical trial data regarding the efficacy and safety of HIF-PH inhibitors for the treatment of anemia because of CKD in both nondialysis-dependent and dialysis-dependent patients, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Go online to PeerView.com/NWK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in nephrology discusses addressing the unmet needs in managing anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants should be better able to: Recognize the burden of anemia in patients with chronic kidney disease, Describe the pathophysiology of anemia in chronic kidney disease, focusing on current and emerging targets for therapeutic intervention, Summarize benefits and limitations associated with current approaches to treat anemia in chronic kidney disease, Describe emerging HIF-PH inhibitors in the context of mechanism of action, efficacy, safety, and potential clinical utilization.

Go online to PeerView.com/NWK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in nephrology discusses addressing the unmet needs in managing anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants should be better able to: Recognize the burden of anemia in patients with chronic kidney disease, Describe the pathophysiology of anemia in chronic kidney disease, focusing on current and emerging targets for therapeutic intervention, Summarize benefits and limitations associated with current approaches to treat anemia in chronic kidney disease, Describe emerging HIF-PH inhibitors in the context of mechanism of action, efficacy, safety, and potential clinical utilization.

Go online to PeerView.com/NWK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in nephrology discusses addressing the unmet needs in managing anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants should be better able to: Recognize the burden of anemia in patients with chronic kidney disease, Describe the pathophysiology of anemia in chronic kidney disease, focusing on current and emerging targets for therapeutic intervention, Summarize benefits and limitations associated with current approaches to treat anemia in chronic kidney disease, Describe emerging HIF-PH inhibitors in the context of mechanism of action, efficacy, safety, and potential clinical utilization.

Go online to PeerView.com/NWK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in nephrology discusses addressing the unmet needs in managing anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants should be better able to: Recognize the burden of anemia in patients with chronic kidney disease, Describe the pathophysiology of anemia in chronic kidney disease, focusing on current and emerging targets for therapeutic intervention, Summarize benefits and limitations associated with current approaches to treat anemia in chronic kidney disease, Describe emerging HIF-PH inhibitors in the context of mechanism of action, efficacy, safety, and potential clinical utilization.

Go online to PeerView.com/NWK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in nephrology discusses addressing the unmet needs in managing anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants should be better able to: Recognize the burden of anemia in patients with chronic kidney disease, Describe the pathophysiology of anemia in chronic kidney disease, focusing on current and emerging targets for therapeutic intervention, Summarize benefits and limitations associated with current approaches to treat anemia in chronic kidney disease, Describe emerging HIF-PH inhibitors in the context of mechanism of action, efficacy, safety, and potential clinical utilization.

Go online to PeerView.com/NWK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in nephrology discusses addressing the unmet needs in managing anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants should be better able to: Recognize the burden of anemia in patients with chronic kidney disease, Describe the pathophysiology of anemia in chronic kidney disease, focusing on current and emerging targets for therapeutic intervention, Summarize benefits and limitations associated with current approaches to treat anemia in chronic kidney disease, Describe emerging HIF-PH inhibitors in the context of mechanism of action, efficacy, safety, and potential clinical utilization.

Go online to PeerView.com/NWK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in nephrology discusses addressing the unmet needs in managing anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants should be better able to: Recognize the burden of anemia in patients with chronic kidney disease, Describe the pathophysiology of anemia in chronic kidney disease, focusing on current and emerging targets for therapeutic intervention, Summarize benefits and limitations associated with current approaches to treat anemia in chronic kidney disease, Describe emerging HIF-PH inhibitors in the context of mechanism of action, efficacy, safety, and potential clinical utilization.

Go online to PeerView.com/NWK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in nephrology discusses addressing the unmet needs in managing anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants should be better able to: Recognize the burden of anemia in patients with chronic kidney disease, Describe the pathophysiology of anemia in chronic kidney disease, focusing on current and emerging targets for therapeutic intervention, Summarize benefits and limitations associated with current approaches to treat anemia in chronic kidney disease, Describe emerging HIF-PH inhibitors in the context of mechanism of action, efficacy, safety, and potential clinical utilization.